Walgreens Health Services > Specialty Pharmacy > Limited-distribution drugs
Limited-distribution drugs
PrintThe following limited-distribution medications are available through Walgreens Specialty Pharmacy. (Manufacturers are listed in parentheses.)
Berinert® (CSL Behring)
For the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients
More information at www.berinert.com
Cimzia® (UCB, Inc.)
For reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy; also for the treatment of adults with moderately to severely active rheumatoid arthritis
More information at www.cimzia.com
H.P. Acthar® Gel (Questcor Pharmaceuticals, Inc.)
For the diagnostic testing of adrenocortical function, and for the treatment of acute exacerbations of multiple sclerosis
More information at www.acthar.com
Hycamtin® capsules (GlaxoSmithKline)
For the treatment of relapsed small cell lung cancer in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy
More information at www.hycamtin.com
Increlex™(Tercica, Inc.)
For the treatment of growth failure in children with severe primary IGF-1 deficiency (primary IGFD) or with growth hormone (GH) deletion who have developed neutralizing antibodies to GH
More information at www.increlex.com
Letairis™(Gilead Sciences, Inc.)
For the treatment of pulmonary arterial hypertension
More information at www.letairis.com
Macugen® ((OSI)™ Eyetech, Inc. and Pfizer, Inc.)
For the treatment of wet age-related macular degeneration
More information at www.macugen.com
Nexavar® (Bayer HealthCare AG)
For the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma
More information at www.nexavar.com
Promacta® (GlaxoSmithKline)
For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
More information at www.promacta.com
Revlimid® (Celgene Corporation)
For the treatment of multiple myeloma and transfusion-dependent anemia due to deletion 5q myelodysplastic syndromes
More information at www.revlimid.com
Supprelin® LA (Indevus Pharmaceuticals, Inc.)
For the treatment of central precocious puberty
More information at www.indevus.com
Synagis® (MedImmune, Inc.)
For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus
More information at www.synagis.com
Tykerb® (GlaxoSmithKline)
For the treatment of advanced or metastatic HER2-positive breast cancer
More information at www.tykerb.com
Tysabri® (Elan Pharmaceuticals, Inc.)
For the treatment of relapsing forms of multiple sclerosis and moderately to severely active Crohn’s disease
More information at www.tysabri.com
Visudyne® (Novartis Pharmaceuticials Corporation)
For the treatment of wet age-related macular degeneration, pathologic myopia, and presumed ocular histoplasmosis
More information at www.visudyne.com
Vivaglobin® (CSL Behring GmbH)
For the treatment of primary immune deficiency
More information at www.vivaglobin.com
Votrient™ (GlaxoSmithKline)
For patients with advanced renal cell carcinoma
More information at us.gsk.com
Xolair® (Genentech, Inc. and Novartis Pharmaceuticals Corporation)
For the treatment of moderate to severe persistent allergic asthma
More information at www.xolair.com
Zorbtive® (EMD Serono, Inc.)
For the treatment of short bowel syndrome
More information at www.zorbtive.com